BALTIMORE--(BUSINESS WIRE)--As part of its continued focus on improving metabolic health, Medifast® (NYSE: MED) today announced that OPTAVIA's comprehensive metabolic health system is available for reimbursement on select insurance plans using Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA). OPTAVIA clients may be able to save up to 40% on program costs by working with their medical provider and insurance administrator to use pre-tax medical funds, offering accessibility for.

Medifast (NYSE: MED) reported fourth-quarter and full-year 2025 results while outlining continued efforts to reposition the business around metabolic health, highlighting early signs of improving coach productivity even as revenue and the active earning coach base declined sharply. Leadership transition and strategic focus Chairman and CEO Dan Chard said he plans to step down as chief

MED posts a wider quarterly loss as revenue tumbles 36.9% on a sharp drop in OPTAVIA coaches, despite beating revenue estimates.

Medifast (MED) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to earnings of $0.1 per share a year ago.

Medifast, Inc. (MED) Q4 2025 Earnings Call Transcript

BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its science-backed, coach-guided lifestyle system, today reported results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Revenue of $75.1 million, with revenue per active earning coach of $4,664 Independent active earning coaches of 16,100 Net loss of $18.1 million, or $1.65 per diluted share ("EPS"), which includes the tax provision charge to establish a non-cash valua.

MED is likely to post a sharp Q4 revenue drop and a wider loss as active earning coaches decline and GLP-1 pressure weighs despite retention and pricing efforts.

Medifast (MED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Medifast (NYSE: MED - Get Free Report) will likely be issuing its Q4 2025 results after the market closes on Tuesday, February 17th. Analysts expect Medifast to post earnings of ($0.80) per share and revenue of $71.40 million for the quarter. Individuals are encouraged to explore the company's upcoming Q4 2025 earning overview page for the

Medifast trades below net cash, with an EV of -$43.68M, reflecting deep skepticism about its OPTAVIA MLM business and turnaround prospects. GLP-1 drugs have rendered MED's weight-loss model largely obsolete, prompting a pivot toward metabolic health services, though execution risk remains high. Despite ongoing losses, MED's cash burn is modest; even with conservative assumptions, shares likely remain a net-net with limited downside over the next year.